Risk factors for drug-induced liver disease

Drug-Induced Liver Disease

Volumn , Issue , 2013, Pages 265-274

  Vuppalanchi, Raj ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol consumption; Daily dose; Drug induced liver injury; Polypharmacy; Risk factors

Indexed keywords

EID: 84882690687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387817-5.00016-9     Document Type: Chapter

References (110)

1. Abboud G., Kaplowitz N. Drug-induced liver injury. Drug Saf 2007, 30:277-294.
2. Vuppalanchi R., Liangpunsakul S., Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol 2007, 102:558-562. [quiz 693].
3. Zimmerman H.J. The spectrum of hepatotoxicity. Perspect Biol Med 1968, 12:135-161.
4. Larson A.M. Acetaminophen hepatotoxicity. Clin Liver Dis 2007, 11:525-548. [vi].
5. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934. [1934 e1-4].
6. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
7. Shapiro M.A., Lewis J.H. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007, 11:477-505. [v].
8. Bell L.N., Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009, 29:337-347.
9. Chalasani N., Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138:2246-2259.
10. Fontana R.J., Watkins P.B., Bonkovsky H.L., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009, 32:55-68.
11. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
12. Suzuki A., Andrade R.J., Bjornsson E., et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010, 33:503-522.
13. Bjornsson E., Ismael S., Nejdet S., et al. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003, 38:86-94.
14. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
15. de Abajo F.J., Montero D., Madurga M., et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004, 58:71-80.
16. Molleston J.P., Fontana R.J., Lopez M.J., et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011, 53:182-189.
17. Dreifuss F.E., Santilli N., Langer D.H., et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987, 37:379-385.
18. Zimmerman H.J. Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981, 141:333-342.
19. Stewart J.D., Horvath R., Baruffini E., et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010, 52:1791-1796.
20. Rivkees S.A. 63 years and 715 days to the "boxed warning": unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010, [2010. pii: 658267].
21. Koch L. Therapy: propylthiouracil use associated with severe hepatotoxicity in children. Nat Rev Endocrinol 2010, 6:416.
22. Black M., Mitchell J.R., Zimmerman H.J., et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975, 69:289-302.
23. Sharma S.K., Balamurugan A., Saha P.K., et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166:916-919.
24. Lucena M.I., Andrade R.J., Fernandez M.C., et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006, 44:850-856.
25. Stock J.G., Strunin L. Unexplained hepatitis following halothane. Anesthesiology 1985, 63:424-439.
26. Braun P. Hepatotoxicity of erythromycin. J Infect Dis 1969, 119:300-306.
27. Stricker B.H., Blok A.P., Claas F.H., et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988, 8:599-606.
28. Koek G.H., Stricker B.H., Blok A.P., et al. Flucloxacillin-associated hepatic injury. Liver 1994, 14:225-229.
29. Fountain F.F., Tolley E., Chrisman C.R., et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005, 128:116-123.
30. Lucena M.I., Andrade R.J., Kaplowitz N., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009, 49:2001-2009.
31. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002, 22:145-155.
32. Banks A.T., Zimmerman H.J., Ishak K.G., et al. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995, 22:820-827.
33. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
34. Bjornsson E., Talwalkar J., Treeprasertsuk S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
35. McKoy J.M., Bennett C.L., Scheetz M.H., et al. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf 2009, 32:147-158.
36. Kappelhoff B.S., van Leth F., Robinson P.A., et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 2005, 10:489-498.
37. Schoenfeld A., Segal J., Friedman S., et al. Adverse reactions to antihypertensive drugs in pregnancy. Obstet Gynecol Surv 1986, 41:67-73.
38. Brewer T. Tetracycline hepatotoxicity. Br Med J 1965, 1:995.
39. Whalley P.J., Adams R.H., Combes B. Tetracycline toxicity in pregnancy. Liver and pancreatic dysfunction. JAMA 1964, 189:357-362.
40. Schultz J.C., Adamson J.S., Workman W.W., et al. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963, 269:999-1004.
41. Schenker S. Tetracycline hepatotoxicity. A review. Mater Med Pol 1976, 8:173-176.
42. Snijdewind I.J., Smit C., Godfried M.H., et al. HCV coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. J Infect 2012, 64:409-416.
43. Natarajan U., Pym A., McDonald C., et al. Safety of nevirapine in pregnancy. HIV Med 2007, 8:64-69.
44. Mitchell S.J., Hilmer S.N., Murnion B.P., et al. Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty. J Clin Pharm Ther 2011, 36:327-335.
45. Warmelink I., ten Hacken N.H., van der Werf T.S., et al. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 2011, 105:400-408.
46. Ugiagbe R.A., Malu A.O., Bojuwoye B.J., et al. Risk factors for hepatotoxicity after introduction of highly active antiretroviral therapy. Exp Clin Hepatol 2011, 7:49-56.
47. Lheureux P.E., Penaloza A., Zahir S., et al. Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence?. Crit Care 2005, 9:431-440.
48. Feher J., Vasarhelyi B., Blazovics A. Halothane hepatitis. Orv Hetil 1993, 134:1795-1798.
49. Malatjalian D.A., Ross J.B., Williams C.N., et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996, 10:369-375.
50. Lee S.S., Buters J.T., Pineau T., et al. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996, 271:12063-12067.
51. Jaeschke H., Gores G.J., Cederbaum A.I., et al. Mechanisms of hepatotoxicity. Toxicol Sci 2002, 65:166-176.
52. Tarantino G., Conca P., Basile V., et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007, 37:410-415.
53. Rutherford A., Davern T., Hay J.E., et al. Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol 2006, 4:1544-1549.
54. El-Serag H.B., Everhart J.E. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002, 122:1822-1828.
55. Xiao Q.H., Deng Z.Z., Liu J.X., et al. Risk factor analysis of hepatic toxicity of antituberculosis agents. Chin J Antibiot 2004, 29:760-761.
56. Chalasani N., Aljadhey H., Kesterson J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287-1292.
57. Lewis J.H., Mortensen M.E., Zweig S., et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46:1453-1463.
58. Vuppalanchi R., Teal E., Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005, 329:62-65.
59. Khorashadi S., Hasson N.K., Cheung R.C. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006, 4:902-907. [quiz 806].
60. Chalasani N., Teal E., Hall S.D. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol 2005, 100:1317-1321.
61. Wong W.M., Wu P.C., Yuen M.F., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000, 31:201-206.
62. Lee B.H., Koh W.J., Choi M.S., et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005, 127:1304-1311.
63. Labarga P., Soriano V., Vispo M.E., et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196:670-676.
64. Ito H., Yoshioka K., Ukai K., et al. The fluctuations of viral load and serum alanine aminotransferase levels in chronic hepatitis C. Hepatol Res 2004, 30:11-17.
65. Jain M.K., Parekh N.K., Hester J., et al. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 2006, 20:817-822.
66. Tilling L., Townsend S., David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006, 26:55-62.
67. Amital H., Arnson Y., Chodick G., et al. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009, 48:1107-1110.
68. Benowitz N.L., Peng M., Jacob P. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 2003, 74:468-474.
69. Czekaj P., Wiaderkiewicz A., Florek E., et al. Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta. Arch Toxicol 2005, 79:13-24.
70. Wada T., Ueda M., Abe K., et al. Risk factor of liver disorders caused by flutamide-statistical analysis using multivariate logistic regression analysis. Hinyokika Kiyo 1999, 45:521-526.
71. Schmidt L.E., Dalhoff K., Poulsen H.E. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002, 35:876-882.
72. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott Williams & Wilkins, Philadelphia. 2nd ed.
73. Whiting-O'Keefe Q.E., Fye K.H., Sack K.D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90:711-716.
74. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
75. Hussain Z., Kar P., Husain S.A. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003, 41:1226-1232.
76. Liguori M.J., Ditewig A.C., Maddox J.F., Luyendyk J.P., Lehman-McKeeman L.D., Nelson D.M., et al. Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: trovafloxacin as an example. Int J Mol Sci 2010, 11(11):4697-4714.
77. Shaw P.J., Ganey P.E., Roth R.A. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010, 118(1):7-18.
78. Laskin D.L., Gardner C.R., Price V.F., et al. Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology 1995, 21:1045-1050.
79. Getachew Y., James L., Lee W.M., et al. Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. Biochem Pharmacol 2010, 79:1363-1371.
80. Gordin F.M., Simon G.L., Wofsy C.B., et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984, 100:495-499.
81. Neuman M.G., Malkiewicz I.M., Phillips E.J., et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit 2002, 24:728-736.
82. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008, 21:84-92.
83. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005, 4:489-499.
84. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 1999, 12:387-395.
85. Lammert C., Einarsson S., Saha C., et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008, 47:2003-2009.
86. Russmann S., Kullak-Ublick G.A., Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009, 16:3041-3053.
87. Lammert C., Bjornsson E., Niklasson A., et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51:615-620.
88. Shear N.H., Spielberg S.P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988, 82:1826-1832.
89. Lewis J.H., Zimmerman H.J., Ishak K.G., et al. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983, 98:984-992.
90. Keeffe E.B., Reis T.C., Berland J.E. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci 1982, 27:701-704.
91. Herron G., Bourdo S. Jaundice secondary to promazine, and an analysis of possible cross sensitivities between phenothiazine derivatives. Gastroenterology 1960, 38:87-90.
92. Andrejak M., Davion T., Gineston J.L., et al. Cross hepatotoxicity between non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) 1987, 295:180-181.
93. Remy A.J., Larrey D., Pageaux G.P., et al. Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur J Gastroenterol Hepatol 1995, 7:373-376.
94. Lucena M.I., Carvajal A., Andrade R.J., et al. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2003, 2:249-262.
95. Spellberg B., Rieg G., Bayer A., et al. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis 2003, 36:1091-1093.
96. Foo H., Gottlieb T. Lack of cross-hepatotoxicity between voriconazole and posaconazole. Clin Infect Dis 2007, 45:803-805.
97. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000, 356:1587-1591.
98. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995, 23(Suppl. 1):16-24.
99. Yun C.H., Okerholm R.A., Guengerich F.P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993, 21:403-409.
100. Steele M.A., Burk R.F., DesPrez R.M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991, 99:465-471.
101. Pessayre D., Bentata M., Degott C., et al. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 1977, 72:284-289.
102. Durand F., Bernuau J., Pessayre D., et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995, 21:929-932.
103. Yasui N., Otani K., Kaneko S., et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995, 17:333-335.
104. Hull M., Jones R., Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. BMJ 1994, 309:378.
105. Ricaurte B., Guirguis A., Taylor H.C., et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006, 40:753-757.
106. Lucena M.I., Andrade R.J., Vicioso L., et al. Prolonged cholestasis after raloxifene and fenofibrate interaction: a case report. World J Gastroenterol 2006, 12:5244-5246.
107. Bryant A.E., Dreifuss F.E. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996, 46:465-469.
108. Gopaul S., Farrell K., Abbott F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 2003, 44:322-328.
109. Siemes H., Nau H., Schultze K., et al. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 1993, 34:332-346.
110. Meier Y., Cavallaro M., Roos M., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005, 61:135-143.